CONNECT WITH US
HealthTech

HealthTech

R&D chief Dean Li says Merck outflanked rivals with its sac-TMT cancer program

Endpoints News logo

Published on

Add as a preferred source on Google
R&D chief Dean Li says Merck outflanked rivals with its sac-TMT cancer program

R&D chief Dean Li says Mer­ck out­flanked ri­vals with its sac-TMT can­cer pro­gram

Mer­ck’s head of R&D Dean Li be­lieves he’s out­foxed his com­pe­ti­tion for the next gen­er­a­tion of on­col­o­gy drugs, jump­ing in­to a wide set of in­di­ca­tions …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Cit­ing 'safe­ty' and 'free­dom,' HHS will al­low com­pound­ing of cer­tain well­ness pep­tides October 28, 2026

Ex­cite­ment, anx­i­ety run­ning high for Bio­gen's piv­otal tri­als dur­ing an­a­lyst call October 28, 2026

One-per­son biotechs and an 'age of mir­a­cles': An­throp­ic re­veals next leg of its bio­phar­ma vi­sion

Up­dat­ed: Lil­ly beats rev­enue fore­casts, lift­ing full-year out­look for third straight quar­ter

Ex­clu­sive: Dren Bio nabs $350M for po­ten­tial 2027 launch of blood can­cer drug



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.